Short communication

Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale

Alberto J. Espay [a, *], Richard Trosch [b], Gustavo Suarez [c], Jonathan Johnson [d], Dominic Marchese [c, 1], Cynthia Comella [e]

[a] *James J and Joan A Gardner Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA*
[b] *Oakland University William Beaumont School of Medicine, Farmington Hills, MI, USA*
[c] *Ipsen Biopharmaceuticals, Basking Ridge, NJ, USA*
[d] *OptumInsight, Eden Prairie, MN, USA*
[e] *Department of Neurology, Rush University Medical Center, Chicago, IL, USA*

ARTICLE INFO

ABSTRACT

Objectives: To characterize the minimal clinically important change (MCIC) after treatment in cervical dystonia patients using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).
Methods: Changes in the TWSTRS from an observational study of abobotulinumtoxinA in the routine management of cervical dystonia (NCT01314365) were analyzed using the Patient Global Impression of Change (PGIC) as anchor.
Results: For the overall population (N = 304, baseline TWSTRS-Total score 43.4 ± 19.4), the MCIC for the TWSTRS Total score was −11.9 (95%CI: −13.9, −10.0; p < 0.0001). However, thresholds ranged from −3.2 to −18.0 dependent on baseline severity. TWSTRS-Total scores improved linearly by 3 points for every one-point PGIC increase. There was similar linearity between the graded PGIC categories and TWSTRS subscale scores (severity, disability, and pain).
Conclusions: A 3-point change is the minimal clinically important change after treatment using TWSTRS as endpoint with higher cutoffs for greater baseline disease severity. For an average trial population (TWSTRS-total: 40—45), a 12-point decrease is clinically meaningful.

© 2018 Elsevier Ltd. All rights reserved.

1. Introduction

Cervical dystonia (CD), the most common form of focal dystonia, is characterized by sustained abnormal muscle contractions causing twisting and turning of the head and neck leading to disabling and sometimes painful postures. Depending on the muscles involved, patients may exhibit torticollis (rotation), laterocollis (tilting), anterocollis (flexion), retrocollis (extension), or combinations thereof Botulinum neurotoxin (BoNT) is recommended as first line treatment for CD.

All trials that led to the approval of currently available BoNTs have utilized the Toronto Western Spasmodic Torticollis Rating Scale (TWSRS) as the primary efficacy measure. The TWSTRS is a comprehensive scale designed to assess objective physical (severity subscale) and subjective findings (disability and pain subscales) [1]. The reliability and validity of the TWSTRS have been well established, and the severity scores rated by physicians positively correlate with patient's self-reported improvement in disability and pain after treatment with BoNT [2]. However, the minimal clinically important change (MCIC) has not yet been established. The MCIC is defined as the smallest change or difference in scores of a measure perceived by patients as beneficial or harmful [3] Ascertaining this number can help assess whether a statistically significant treatment effect is sufficiently large enough to be interpreted as clinically significant and could help personalize treatment in clinical practice.

ANCHOR-CD was a prospective, open-label, observational registry designed to evaluate the efficacy and safety of a BoNT-A formulation (abobotulinumtoxinA, Dysport® Ipsen Biopharmaceuticals) for the long-term treatment (≈ 1 year) of adult

* Corresponding author. University of Cincinnati, College of Medicine, 260 Stetson Street, Suite 2300, PO Box 670525, Cincinnati, OH, 45267-0525, United States.
   E-mail address: alberto.espay@uc.edu (A.J. Espay).
   [1] Present address: Westerville, Ohio, USA.

idiopathic CD in routine clinical practice in the United States [4]. All patients enrolled into this registry underwent regular comprehensive assessments, including the clinician-rated TWSTRS scale and the patient-rated global impression of change (PGIC). Thus, the study design provides a rich dataset upon which the MCIC can be examined by determining the relationship between the patient perception of treatment response and the corresponding reduction in TWSTRS scores, with the main objective of calculating the MCIC on the TWSTRS-Total score and subscores according to patients' self-reported PGIC scores.

2. Methods

2.1. ANCHOR-CD study design

ANCHOR-CD was a prospective, open-label, observational study (NCT01314365) of abobotulinumtoxinA in the routine treatment of CD, described in detail elsewhere [4]. Briefly, adult (aged ≥18 years) patients diagnosed with primary idiopathic CD were enrolled at 41 US sites. Patients could be BoNT-naïve or previously treated with BoNT if ≥ 12 weeks had elapsed since the last injection. The decision to prescribe abobotulinumtoxinA was to be made before and independently from the decision to enroll the patient in the registry.

AbobotulinumtoxinA was administered over 4 treatment cycles. The sites, number of injections, and doses were determined by each investigator in accordance with their standards of clinical practice and in line with the United States Prescribing Information for Dysport®. In-office assessments of TWSTRS were made at baseline and at Week 4 following the injection. The PGIC was assessed at Week 4 using a 7-point Likert scale, ranging from +3 (very much improved) to −3 (very much worse).

2.2. Analyses

Data from the first treatment cycle were used. *Post-hoc* analyses were performed in the modified intent to treat (mITT) population which included all treated patients who had a documented TWSTRS severity score at Cycle 1 baseline, and at Week 4; and, a documented PGIC response value at Week 4. Due to sample size imbalances in the worsening categories, we modified the PGIC categories such that scores of −1 to −3 were combined into a "worsened" group resulting in 5 categories: "very much improved" (+3), "much improved" (+2), "minimally improved" (+1), "no change" (0) and "worsened" (−1 to −3). Mean ± SD TWSTRS-Total score changes from baseline to the Week 4 assessments and their 95% confidence intervals (CIs) in each of the different categories of the PGIC were calculated and were compared with 'no change' using paired t-tests.

Ordinary least squares regression analyses were used to measure the slope of TWSTRS-Total scores across modified PGIC categories. The change in TWSTRS-Total scores served as the dependent variable and PGIC as the independent variable (assuming a linear relationship). The MCIC was calculated using patients' report of a minimal improvement (+1) in their PGIC, for the total population and for quartiles of baseline TWSTRS-Total score (0−28.5, 28.5−41.0, 41.0−52.0, 52.0+).

3. Results

As described previously, 347 of 350 enrolled patients (86 men, 261 women) received at least one dose of abobotulinumtoxinA treatment (ITT population) [4]. Of these, 304 patients had documented TWSTRS severity and PGIC scores at baseline and at the end of Cycle 1- Week 4 (mITT population). For the mITT population,

mean TWSTRS-Total score was 43.4 ± 19.4 at baseline; most patients (67.2%) had a complex form of CD, with 25.6% reported as exhibiting pure torticollis. Overall, 72.6% of patients had received previous BoNT treatment for CD.

In the mITT analysis, the average mean decrease (from baseline to Week 4) in TWSTRS-Total scores for PGIC categories ranged from −5.89 (p < 0.01) in the "worsened" group to −19.63 in the "very much improved" group (Fig. 1a). Assuming an equal distance between the modified PGIC categories, the relationship between TWSTRS-Total scores and improved/no change PGIC categories was found to be linear in the mITT population. The least squares regression slope for PGIC categories was 2.9 ± 0.51 (p < 0.0001), which suggests that TWSTRS-Total scores improved by 2.9 points for every 1 point increase in PGIC rating. There was similar linearity between the graded PGIC categories and baseline Total and subscale TWSTRS scores (severity, disability, and pain), regardless of treatment status (BoNT previously treated and naïve populations) (Fig. 1b).

Overall, for the total mITT population (mean baseline TWSTRS-Total score of 43.4 ± 19.4), the mean (95% CI) change in TWSTRS-Total scores in those patients who rated minimally improved (+1) on the PGIC at Week 4 was −11.9 (−13.9, −10.0) (p < 0.0001). Further analysis showed a range of MCIC dependent on baseline severity based on TWSTRS-Total scores, when assessing mean change in TWSTRS based on baseline quartiles (Table 1). The mean (95% CI) MCIC ranged from −3.18 (−7.6, 1.3) for the lowest baseline TWSTRS quartile to −18.0 (−20.3, −15.7) for the highest TWSTRS quartile.

4. Discussion

To our knowledge, this is the first study to characterize a MCIC for the TWSTRS. In our analyses, the MCIC ranged from −3.2 for patients with a baseline TWSTRS-Total score of ≤28.5 up to −18.0 for patients with a baseline TWSTRS-Total score of >52. For an average trial population with a baseline TWSTRS-total score between 40 and 45, we suggest that a decrease of approximately 12 points should be considered clinically meaningful. Our findings also show that the patient perception of change is linearly associated with the TWSTRS scale. Furthermore, TWSTRS-Total scores improved by 3 points for every 1-point increase in PGIC, regardless of disease severity or prior treatment status.

Previous clinical trials have predefined 'response' to BoNT treatment as a reduction of at least 30% from baseline TWSTRS-Total scores [5,6]. While such definitions have been based on clinical experience rather than scale clinimetrics, our results showing the relationship between baseline score and change from baseline support the validity of this approach. Furthermore, our results provide the first quantitative TWSTRS cutoffs for assessment of response based on quartiles of baseline scores, which may better assist with future clinical trial design and interpretation of the clinical relevance of any therapeutic response. For example, in the recent randomized placebo-controlled trial of abobotulinumtoxinA compared to its new liquid formulation, a treatment difference of 1.5 points between the two active groups may not be clinically relevant (whereas the differences of 14.0 points and 12.5 points for the respective active treatments vs. placebo are above the MCIC) [7]. The apparent linear relationship between TWSTRS-Total scores and PGIC categories is also of interest for future clinical trial design and appears to be supported by data from another registry of abobotulinumtoxinA, INTEREST-IN CD1, in which 73.6% of patients treated after one cycle of abobotulinumtoxinA were reported to have ≥25% improvement in TWSTRS-Total scores and 69.8% of patients self-reported an improvement in PGIC [8].

This analysis should be considered a first step in understanding